Phase 1 Cholangiocarcinoma Clinical Trials
32 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 32 trials
Recruiting
Phase 1Phase 2
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting
Phase 1
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 1Phase 2
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Biliary Tract CancerCholangiocarcinomaExtrahepatic Cholangiocarcinoma+2 more
Beijing Biotech30 enrolled1 locationNCT07641036
Recruiting
Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled30 locationsNCT07213791
Recruiting
Phase 1
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Refractory Malignant Solid Neoplasm+4 more
University of Southern California36 enrolled2 locationsNCT05791448
Recruiting
Phase 1
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Gallbladder CancerBiliary Tract NeoplasmsCholangiocarcinoma, Intrahepatic+2 more
Shanghai Zhongshan Hospital18 enrolled1 locationNCT07614061
Recruiting
Phase 1
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Hepatocellular Carcinoma (HCC)Gastric Cancer (GC)+1 more
Shenzhen Xinhe Biomedical48 enrolled2 locationsNCT07594964
Recruiting
Phase 1Phase 2
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Gastric CancersColorectal, CancerPancreatic Cancer+1 more
Bold Therapeutics, Inc.220 enrolled24 locationsNCT04421820
Recruiting
Phase 1Phase 2
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Cholangiocarcinoma
Genfit74 enrolled11 locationsNCT05874414
Recruiting
Phase 1
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
CholangiocarcinomaAdvanced Solid TumorMetastatic Solid Tumor+1 more
Massachusetts General Hospital70 enrolled1 locationNCT06302621
Recruiting
Phase 1
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma+2 more
Mayo Clinic16 enrolled1 locationNCT06058663
Recruiting
Phase 1
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Ovarian CancerMesothelioma, MalignantCholangiocarcinoma Recurrent
Verismo Therapeutics42 enrolled5 locationsNCT05568680
Recruiting
Phase 1
A Study of PHST001 in Advanced Solid Tumors
Ovarian CancerEndometrial CancerCholangiocarcinoma+2 more
Pheast Therapeutics272 enrolled20 locationsNCT06840886
Recruiting
Phase 1Phase 2
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier52 enrolled38 locationsNCT06501625
Recruiting
Phase 1
A Study of MGC028 in Participants With Advanced Solid Tumors
CholangiocarcinomaColorectal CarcinomaPancreatic Carcinoma+2 more
MacroGenics124 enrolled7 locationsNCT06723236
Recruiting
Phase 1Phase 2
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma+3 more
Mayo Clinic85 enrolled1 locationNCT03942328
Recruiting
Phase 1Phase 2
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Colorectal, CancerUrothelial CarcinomaSquamous Non-small-cell Lung Cancer+2 more
Alentis Therapeutics AG180 enrolled28 locationsNCT07169734
Recruiting
Phase 1
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
Intrahepatic CholangiocarcinomaGallbladder CarcinomaMetastatic Malignant Neoplasm in the Peritoneum+5 more
City of Hope Medical Center12 enrolled1 locationNCT05285358
Recruiting
Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
CholangiocarcinomaBenign Liver TumorAdult Hepatocellular Carcinoma+2 more
M.D. Anderson Cancer Center110 enrolled1 locationNCT02379377
Recruiting
Phase 1Phase 2
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Advanced CholangiocarcinomaFGFR2 Fusion
M.D. Anderson Cancer Center25 enrolled1 locationNCT06439485